Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 107
- Registration Number
- NCT05804162
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
Electrophysiological Effects of Potential QT Prolonging Drugs
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 44
- Registration Number
- NCT05716854
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT05668936
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05630274
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 94
- Registration Number
- NCT05580003
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇧🇪Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT05566288
- Locations
- 🇵🇹
BlueClinical Phase I, Porto, Portugal
A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People
- Conditions
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT05508776
- Locations
- 🇬🇧
LEO Investigational Site, Leeds, United Kingdom
A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT05481528
- Locations
- 🇩🇪
NUVISAN GmbH Neu-Ulm, Neu-Ulm, Bayern, Germany
An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics
- Conditions
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05478278
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.